There's no question in my mind that Teva is trying to relieve the impact of generic Copaxone. As long as they continue with their decent free cash flow I think we'll see more deals or partnerships out of them.
Their OGXI partnership last year was a 1st for them, then they came along with the PG and now Cephalon deals.
Market Data 
Markets 
AI
